A pooled analysis of mortality in patients with COPD receiving triple therapy versus dual bronchodilation

Marc Miravitlles, P M Calverley, Katia M.C. Verhamme, Michael Dreher, Valentina Bayer, Asparuh Gardev, Alberto de la Hoz, Jadwiga A Wedzicha, David Price

Research output: Contribution to journalAbstractpeer-review

8 Downloads (Pure)

Abstract

Recent studies report a possible mortality benefit of treatment with long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS) versus LAMA/LABA combinations in patients with highly symptomatic COPD and a history of exacerbations (≥1 moderate or severe exacerbation in the previous year). We compared the time to all-cause mortality with LAMA/LABA/ICS versus LAMA+LABA in a population of patients with predominantly moderateto-severe COPD and a predominantly lower exacerbation risk.
Original languageEnglish
Article numberA2251
Number of pages1
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume203
Early online date19 May 2021
DOIs
Publication statusPublished - 2021
EventATS International Conference Committee: ATS 2021 - Virtual event
Duration: 14 May 202119 May 2021
https://conference.thoracic.org/

Fingerprint

Dive into the research topics of 'A pooled analysis of mortality in patients with COPD receiving triple therapy versus dual bronchodilation'. Together they form a unique fingerprint.

Cite this